VTYX Q1 2023 Earnings — Ventyx Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

VTYXVentyx Biosciences, Inc.

$1B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$43M

Net Income

-$39M

EPS (Diluted)

$-0.61

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$389M

Total Liabilities

$18M

Stockholders' Equity

$372M

Cash & Equivalents

$64M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$43M	-$23M	-87.1%
Net Income	-$39M	-$23M	-71.3%